These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 25065834)

  • 1. Influences on visit retention in clinical trials: insights from qualitative research during the VOICE trial in Johannesburg, South Africa.
    Magazi B; Stadler J; Delany-Moretlwe S; Montgomery E; Mathebula F; Hartmann M; van der Straten A
    BMC Womens Health; 2014 Jul; 14():88. PubMed ID: 25065834
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Women's experiences with oral and vaginal pre-exposure prophylaxis: the VOICE-C qualitative study in Johannesburg, South Africa.
    van der Straten A; Stadler J; Montgomery E; Hartmann M; Magazi B; Mathebula F; Schwartz K; Laborde N; Soto-Torres L
    PLoS One; 2014; 9(2):e89118. PubMed ID: 24586534
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Male Partner Influence on Women's HIV Prevention Trial Participation and Use of Pre-exposure Prophylaxis: the Importance of "Understanding".
    Montgomery ET; van der Straten A; Stadler J; Hartmann M; Magazi B; Mathebula F; Laborde N; Soto-Torres L
    AIDS Behav; 2015 May; 19(5):784-93. PubMed ID: 25416076
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Perspectives on use of oral and vaginal antiretrovirals for HIV prevention: the VOICE-C qualitative study in Johannesburg, South Africa.
    van der Straten A; Stadler J; Luecke E; Laborde N; Hartmann M; Montgomery ET;
    J Int AIDS Soc; 2014; 17(3 Suppl 2):19146. PubMed ID: 25224610
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Experiences with HPTN 067/ADAPT Study-Provided Open-Label PrEP Among Women in Cape Town: Facilitators and Barriers Within a Mutuality Framework.
    Amico KR; Wallace M; Bekker LG; Roux S; Atujuna M; Sebastian E; Dye BJ; Elharrar V; Grant RM
    AIDS Behav; 2017 May; 21(5):1361-1375. PubMed ID: 27317411
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Understanding women's motivations to participate in MTN-003/VOICE, a phase 2b HIV prevention trial with low adherence.
    Katz AWK; Mensch BS; Woeber K; Musara P; Etima J; van der Straten A
    BMC Womens Health; 2019 Jan; 19(1):18. PubMed ID: 30683103
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Negotiating the use of female-initiated HIV prevention methods in a context of gender-based violence: the narrative of rape.
    Hartmann M; Montgomery E; Stadler J; Laborde N; Magazi B; Mathebula F; van der Straten A
    Cult Health Sex; 2016; 18(6):611-24. PubMed ID: 26551920
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The influence of HIV-related stigma on PrEP disclosure and adherence among adolescent girls and young women in HPTN 082: a qualitative study.
    Velloza J; Khoza N; Scorgie F; Chitukuta M; Mutero P; Mutiti K; Mangxilana N; Nobula L; Bulterys MA; Atujuna M; Hosek S; Heffron R; Bekker LG; Mgodi N; Chirenje M; Celum C; Delany-Moretlwe S;
    J Int AIDS Soc; 2020 Mar; 23(3):e25463. PubMed ID: 32144874
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Misreporting of Product Adherence in the MTN-003/VOICE Trial for HIV Prevention in Africa: Participants' Explanations for Dishonesty.
    Montgomery ET; Mensch B; Musara P; Hartmann M; Woeber K; Etima J; van der Straten A
    AIDS Behav; 2017 Feb; 21(2):481-491. PubMed ID: 27858268
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hidden harms: women's narratives of intimate partner violence in a microbicide trial, South Africa.
    Stadler J; Delany-Moretlwe S; Palanee T; Rees H
    Soc Sci Med; 2014 Jun; 110():49-55. PubMed ID: 24721447
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stated product formulation preferences for HIV pre-exposure prophylaxis among women in the VOICE-D (MTN-003D) study.
    Luecke EH; Cheng H; Woeber K; Nakyanzi T; Mudekunye-Mahaka IC; van der Straten A;
    J Int AIDS Soc; 2016; 19(1):20875. PubMed ID: 27247202
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influences of geo-spatial location on pre-exposure prophylaxis use in South Africa: positioning microbicides for better product uptake.
    Govender EM; Mansoor LE; Abdool Karim Q
    AIDS Care; 2017 Jun; 29(6):734-740. PubMed ID: 27799005
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The importance of choice in the rollout of ARV-based prevention to user groups in Kenya and South Africa: a qualitative study.
    Mack N; Evens EM; Tolley EE; Brelsford K; Mackenzie C; Milford C; Smit JA; Kimani J
    J Int AIDS Soc; 2014; 17(3 Suppl 2):19157. PubMed ID: 25224616
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PrEP uptake, persistence, adherence, and effect of retrospective drug level feedback on PrEP adherence among young women in southern Africa: Results from HPTN 082, a randomized controlled trial.
    Celum C; Hosek S; Tsholwana M; Kassim S; Mukaka S; Dye BJ; Pathak S; Mgodi N; Bekker LG; Donnell DJ; Wilson E; Yuha K; Anderson PL; Agyei Y; Noble H; Rose SM; Baeten JM; Fogel JM; Adeyeye A; Wiesner L; Rooney J; Delany-Moretlwe S
    PLoS Med; 2021 Jun; 18(6):e1003670. PubMed ID: 34143779
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of Male Partner Involvement on Women's Adherence to the Dapivirine Vaginal Ring During a Phase III HIV Prevention Trial.
    Roberts ST; Nair G; Baeten JM; Palanee-Philips T; Schwartz K; Reddy K; Kabwigu S; Matovu Kiweewa F; Govender V; Gaffoor Z; Singh N; Siva S; Naidoo K; Montgomery ET;
    AIDS Behav; 2020 May; 24(5):1432-1442. PubMed ID: 31667678
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Degrees of disclosure: a study of women's covert use of the diaphragm in an HIV prevention trial in sub-Saharan Africa.
    Sahin-Hodoglugil NN; van der Straten A; Cheng H; Montgomery ET; Kacanek D; Mtetwa S; Morar N; Munyoro J; Padian N;
    Soc Sci Med; 2009 Nov; 69(10):1547-55. PubMed ID: 19765879
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Women design their own vaginal microbicide trial: Suggestions on how to improve adherence from former participants of HIV prevention trials.
    Miller L; Morar N; Kapiga S; Ramjee G; Hayes R
    PLoS One; 2021; 16(1):e0244652. PubMed ID: 33411782
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protocol for an open-label, single-arm trial of HIV pre-exposure prophylaxis (PrEP) among people at high risk of HIV infection: the NSW Demonstration Project PRELUDE.
    Vaccher S; Grulich A; McAllister J; Templeton DJ; Bloch M; McNulty A; Holden J; Poynten IM; Prestage G; Zablotska I;
    BMJ Open; 2016 Jun; 6(6):e012179. PubMed ID: 27324719
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The relationship between vaginal ring use and intimate partner violence and social harms: formative research outcomes from the CHARISMA study in Johannesburg, South Africa.
    Hartmann M; Palanee-Phillips T; O'Rourke S; Adewumi K; Tenza S; Mathebula F; Wagner D; Ayub A; Montgomery ET
    AIDS Care; 2019 Jun; 31(6):660-666. PubMed ID: 30309246
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A qualitative study to identify critical attributes and attribute-levels for a discrete choice experiment on oral pre-exposure prophylaxis (PrEP) delivery among young people in Cape Town and Johannesburg, South Africa.
    Dietrich JJ; Atujuna M; Tshabalala G; Hornschuh S; Mulaudzi M; Koh M; Ahmed N; Muhumuza R; Ssemata AS; Otwombe K; Bekker LG; Seeley J; Martinson NA; Terris-Prestholt F; Fox J
    BMC Health Serv Res; 2021 Jan; 21(1):17. PubMed ID: 33407395
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.